NOVOMEDLINK™
  1. Activella®

    (estradiol/norethindrone acetate tablets)

  2. Vagifem®

    (estradiol vaginal tablets)

  3. Levemir®

    (insulin detemir [rDNA origin] injection)

  4. Norditropin®

    (somatropin (rDNA origin) injection)

  5. NovoLog®

    (Insulin aspart [rDNA origin] injection)

  6. NovoLog® Mix 70/30

    (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])

  7. NovoSeven®

    (Coagulation Factor VIIa [Recombinant])

Clinical Information About NovoLog®

NovoLog® is a rapid-acting bolus insulin that can help your patients achieve glycemic control

Whether used with a basal insulin or delivered through a subcutaneous pump, the convenient mealtime dosing fits your patients' individualized needs.

NovoLog® is quickly absorbed, so it starts to work almost immediately

NovoL insulin pen

Find out about the benefits of NovoLog®, including its:


  1. NovoLog® (Insulin aspart [rDNA origin] injection) Indications and Usage

    NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

    NovoLog® is indicated for the treatment of patients with diabetes mellitus for the control of hyperglycemia.

    NovoLog® Important Safety Information

    NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. Because of the fast onset of action, the injection of NovoLog® should be immediately followed by a meal. Because of the short duration of action of NovoLog®, patients with diabetes also require a longer-acting insulin to maintain adequate glucose control. NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog®.

    Any change in insulin should be made cautiously and only under medical supervision. The time course of action of insulin and insulin analogs such as NovoLog® may vary considerably in different individuals or within the same individual. A1C levels did not differ between patients treated with regular human insulin and those treated with NovoLog®.

    Differences in pharmacokinetics and pharmacodynamics between NovoLog® and regular human insulin are not associated with differences in overall glycemic control.

    In controlled clinical trials, allergic reactions were reported in 3 of 735 patients (0.4%) who received regular human insulin and 10 of 1394 patients (0.7%) who received NovoLog®. Levels of antibodies that cross-react with human insulin and insulin aspart were transiently increased in type 1 patients treated with NovoLog® compared with regular human insulin and no longer evident at 12 months of treatment. As with other insulins, NovoLog® dose requirements may be reduced in the presence of renal impairment or hepatic dysfunction.

    Pump or infusion set malfunctions or insulin degradation can lead to hyperglycemia and ketosis in a short time because of the small subcutaneous depot of insulin. This is especially pertinent for rapid-acting insulin analogs that are more rapidly absorbed and have shorter durations of action. These differences may be particularly relevant when patients are switched from multiple injection therapy or infusion with buffered regular insulin.

    Please see Prescribing Information.

Levemir®, NovoLog®, NovoLog® Mix 70/30, FlexPen® and Norditropin® are registered trademarks of Novo Nordisk A/S. NovoSeven® is a registered trademark of Novo Nordisk Health Care AG. Activella® 1.0 mg/0.5 mg and Activella® 0.5 mg/0.1 mg and Vagifem® are registered trademarks of Novo Nordisk FemCare AG.